IPO Market Gained Strength in 2025

U.S. IPO activity rebounded sharply in 2025 with 354 equity IPOs (up 136 from 2024) and non-SPAC IPOs raising $44 billion (+$14bn vs. 2024); 81% of new listings chose Nasdaq, raising $25 billion on IPO day. Big raises included Medline ($6.26bn), CoreWeave ($1.5bn), SailPoint ($1.38bn) and Firefly (~$999m); median day-one IPO pop was 13% (average 22%, 71% positive). SPAC issuance recovered materially (median SPAC raise $200m, many still searching for targets) and active SPAC prices averaged ~$10.47; sector performance was mixed — Health Care +39% average to year-end while Information Technology averaged -33% — supporting a cautiously optimistic outlook for continued strong issuance into 2026.

Analysis

Market structure: Exchanges, lead managers and healthcare IPO issuers are clear winners — Nasdaq-listed deals accounted for 81% of new listings and exchange fee capture (NDAQ) should rise as activity increases; expect incremental listing revenue of ~5–10% yoy if IPO cadence persists into H1–H2 2026. Smaller IT and energy IPOs look vulnerable: IT had the largest raise ($11.2B) but a year-end avg return of -33%, signaling weaker pricing power and secondary market demand for small-cap tech. SPACs reopening (median raise ≈ $200M, price cluster ~$10.3) shifts supply toward controllable aftermarket arbitrage but also raises redemption/liquidity risk in 12–30 months.

Risk assessment: Tail risks include a regulatory crackdown on SPAC sponsor economics or lock-up/secondary selling from centicorn IPOs (SpaceX/OpenAI/Databricks) that could dump $100s of billions of supply — low probability but >30% conditional impact on small-cap multiples. Time horizons: days — elevated intraday volatility around IPOs; weeks–months — median IPO pop fade (~13% median day-one) typically reverses some gains over 3–6 months; long-term (12–24 months) depends on Fed policy and whether the $3T potential 2026 pipeline materializes. Hidden dependencies: VC fund liquidity needs and lock-up expiries drive forced selling; secondary offerings from top private names are a binary catalyst.

Trade implications: Tactical trades should overweight exchange exposure (NDAQ) and select healthcare IPOs (e.g., MDLN on >10% pullback) while shorting baskets of small-cap IT IPOs via IPO ETF put spreads (target -20% realized). SPAC strategy: buy pre-deal SPACs trading < $9.90 (mean reversion to $10.50) sized 0.5–1% with 6–12 month horizons; short non-announced SPACs > $11 where premium >10% to NAV. Use options to capture fade: sell 3-month covered calls on recent winners and buy 6–12 month put spreads on small-cap tech IPO cohort to limit downside.

Contrarian angles: The consensus of a uninterrupted IPO boom underestimates dilution/secondary supply risk — centicorn listings could temporarily depress multiples, especially in tech; healthcare outperformance in 2025 (avg +39%) suggests a persistent sector skew that markets may underprice. Unicorn premium has compressed — cap-weighted return only 6.5% in 2025 — so avoid paying structural premiums for megacap private names without clear cashflow paths. Historically (post-2000/2008 recoveries) late-cycle issuance surges precede a mean reversion of small-cap IPO returns; size positions accordingly and favor liquidity-rich instruments.

Key Decisions for Investors

• Establish a 2–3% portfolio long in Nasdaq (NDAQ) common stock with a 3–9 month horizon; trim if NDAQ appreciates >25% or falls >10% from entry; thesis: higher listing volumes and fee capture as IPO cadence continues.
• Initiate a 1.5–2% tactical long position in high-quality healthcare IPOs (target MDLN on a pullback ≥10% from day-one close) with a 6–12 month target return of 20–40%; hedge by selling 3-month covered calls at ~+15% OTM to finance position.
• Enter a relative-value pair: long a 6–12 month basket of top-2025 healthcare IPOs (equal-weight, 1% total) and short the tech IPO ETF (e.g., IPOE) via 6–9 month 10–15% put spreads sized 1% to capture expected tech IPO underperformance vs healthcare.
• SPAC arbitrage: allocate 0.5–1% to buying active SPACs trading < $9.90 (avg price 10.47) with >12 months to find deals; target mean reversion to $10.50 within 3–9 months and exit if NAV-based redemptions appear or price drops below $9.50.
• Risk control: reduce concentrated exposure to small-cap IT IPOs by 20–40% vs benchmark; buy 6–12 month index or cohort put spreads if the 10‑year yield moves +50bp from current levels or if SEC issues new SPAC/regulatory guidance within next 60 days.